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ABSTRACT
LTB4, a proinflammatory lipid mediator generated from arachidonic acid through the action of 5-lipoxygenase,
has been known for over two decades and is implicated in a wide variety of inflammatory disorders. BLT1, a G-
protein-coupled receptor, has recently been identified as a high affinity receptor specific for LTB4. Recent stud-
ies in allergen-induced airway hyperresponsiveness and inflammation using mice lacking BLT1 have shown
crucial new roles for leukotriene B4 and BLT1 in Th2 cytokine IL-13 production from lung T cells and recruit-
ment of antigen-specific effector CD8+ T cells, suggesting novel mechanisms for their actions. The leukotriene
B4-BLT1 pathway is an important target for the treatment of bronchial asthma.
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INTRODUCTION
Allergic asthma is a complex syndrome which has
been characterized by airway obstruction, airway in-
flammation and airway hyperresponsiveness (AHR). 1,2
Allergen-specific memory T cells and antibody are
thought to play a central role in the development of
these responses. 2,3 Recent studies in both humans
and rodents have indicated that in addition to CD4+ T
cells, CD8+ T cells may play an important role in the
development of allergic airway responses. 4-10
Leukotriene B4 (LTB4)is a potent lipid inflamma-
tory mediator derived from membrane phospholipids
by the sequential action of cytosolic phospholipase
A2, 5-lipoxygenase and leukotriene A4 hydrolase.11,12
LTB4 is a chemoattractant for leukocytes, including
neutrophils , macrophages, monocytes , and eosino-
phils.13-16 LTB4 has classically been thought to be an
important mediator of the early phase of the asth-
matic response to inhaled allergens.17 Recently, the
receptors for LTB4 have been identified, and LTB4 is
thought to activate leukocytes through a G protein-
coupled cell surface receptor, BLT1.18,19 As we dis-
cuss here, the discovery of BLT1 and recent experi-
ments using mice that are deficient in BLT1 have re-
vealed important roles for this LTB4-BLT1 pathway in
IL-13 production from lung T lymphocytes and re-
cruitment of effector CD8+ T cells in allergen-induced
airway hyperresponsiveness and inflammation
GENERATION OF LTB4
Leukotrienes are generated by the metabolism of ara-
chidonic acid. The first committed step in the leukot-
riene biosynthesis is conversion of arachidonic acid
to leukotriene A 4 ( LTA 4 ) by the enzyme 5-
lipoxygenase (5-LO).11 Leukotrienes do not exist pre-
formed in cells but are synthesized from the break-
down of arachidonic acid. They can be released from
phospholipids in intact cells following stimulation, in-
fection or injury by the action of cytosolic phospholi-
pase A2. The free arachidonic acid is sequestered at
the nuclear envelope and brought into contact with 5-
LO by an accessory protein named 5-LO-activating
protein (FLAP). 5-LO converts arachidonic acid to
LTA4, which is unstable and is hydrolyzed by LTA4
hydrolase (LTA4H), to form LTB4
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The leukotrienes are formed in different cell types
as well as via transcellular metabolism involving mul-
tiple cells such as neutrophils, platelets, and vascular
cells.20-22 Human neutrophils and eosinophils synthe-
size LTB4 and LTC4, respectively . 13,23 Monocytes
and macrophages also synthesize both LTB4 and the
cys-LTs.24 LTC4 is metabolized to LTD4 and LTE4 by
the cells in which this mediator is formed. In addi-
tion, the cys-LTs can be transformed into 6-trans -
LTB4 by hypochlorous acid, which is generated dur-
ing the respiratory burst in leukocytes.25,26 LTB4 is
also metabolized in the cells which produce this me-
tabolite, by a unique membrane bound cytochrome P
450 enzyme.27
RECEPTORS FOR LTB4
Although LTB4 was one of the earliest leukocyte
chemoattractants identified, its receptors have been
elusive. The human high-affinity receptor was cloned
by Yokomizo et al. in 1997 from differentiated HL-60
cells and provided a molecular tag for LTB4 activi-
ties. 18 A second, low-affinity LTB4 receptor , BLT2
was also identified by Yokomizo et al..19 Both recep-
tors are members of the G-protein-coupled seven-
transmembrane-domain receptor superfamily, whose
genes are located in very close proximity to each
other in the human as well as mouse genomes. The
two receptors differ in their affinity and specificity for
LTB4. BLT1 is a high affinity receptor specific for
LTB4, whereas BLT2 is a low affinity receptor which
also binds other eicosanoids . These two receptors
also differ in their expression pattern: BLT1 is ex-
pressed primarily on leukocytes, whereas BLT2 is ex-
pressed more ubiquitously.16
LTB4 was classically described as a chemoattrac-
tant for myeloid leukocytes,13,28 and BLT1 was shown
to be expressed on granulocytes , macrophages ,
monocytes and eosinophils, and to a lesser extent on
naive lymphocytes.15,16,29-32 These findings were con-
sistent with the classical notion that LTB4 is a local
inflammatory mediator. However, recent studies have
suggested that it also acts as an important attractant
for differentiated T cells. Subsequently, BLT1 expres-
sion on mouse CD4+ T cells33 that have been differ-
entiated in vitro to effector phenotypes has been re-
ported. CD4+ T cells that were activated in vitro un-
der non-polarizing (TH0), TH1-polarizing, or TH2-
polarizing conditions all had increased levels of
mRNA encoding BLT1 compared with naive cells ,
which expressed little BLT1.33 By contrast, expres-
sion of BLT2 by naive T cells or by TH0, TH1 or TH2
effector cells was not detected. BLT1 expression has
also been shown to be induced in CD4+ T cells that
leave the lymph node and enter the tissue after activa-
tion by antigen in vivo in intact mice.33
BLT1 expression on mouse CD8+ T cells that have
been differentiated in vitro to effector phenotypes has
also been reported.34,35 Antigen-experienced popula-
tions of memory CD8+ T cells can be distinguished
by the surface expression of CD62 ligand (CD62L)
and the chemokine receptor CCR7. Different func-
tional and migratory properties have been recently
ascribed to these cells.36-38 Antigen-experienced cen-
tral memory CD8+ T cells (TCM) are CD62LhiCCR7
hi and home preferentially to lymph nodes. Effector
CD8+ T cells (TEFF) are CD62LloCCR7lo and traffic
more efficiently to nonlymphoid tissues and to sites
of tissue inflammation. In vitro, CD8+ T cells can be
differentiated in culture to either of these subtypes.
When cultured in the presence of IL-15, antigen-
specific CD8+ T cells acquire the phenotypic and
functional characteristics of CD 8 + TCM, whereas
CD8+ T cells cultured in the presence of IL-2 show
characteristics of CD8+ TEFF cells.38,39 It has been re-
ported that TCM or naive CD8+ T cells expressed little
mRNA encoding BLT1 whereas BLT1 expression on
TEFF was upregulated.34,35
LTB4 CONTRIBUTES TO THE RECRUIT-
MENT AND ACTIVATION OF NEUTROPHILS
AND EOSINOPHILS
Studies in human have suggested the importance of
LTB4 in asthma. For example, it has been reported
that the levels of 5-LO and LTA4H were increased in
the airways and circulating neutrophils of patients
with asthma.40,41 Increased levels of LTB4 have also
been shown in the blood , BAL fluid , and exhaled
breath condensates of patients with asthma . 42-47 In
contrast to the cysteinyl leukotrienes, which are po-
tent mediators of bronchoconstriction , 48 LTB 4 is
thought to be a proinflammatory mediator, and the
classical major activities of LTB4 are the recruitment,
activation and prolongation of survival of myeloid leu-
kocytes including neutrophils and eosinophils.13,49-52
As to a pathogenic role for neutrophils in asthma ,
large numbers of neutrophils have been found in the
airways of patients with asthma who were suffering
clinical exacerbations or status asthmaticus. 50-53 Pa-
tients who suffered a sudden asthma-related death
also showed increased numbers of neutrophils in the
lungs.54 A correlation between eosinophil numbers in
the airways and disease severity55 and a study utiliz-
ing mice lacking eosinophils 56 have indicated the
pathological role of eosinophils in asthma. A study in
mice indicated that LTB4 and BLT1 participate in the
early phase recruitment of eosinophils and neutro-
phils to the airways.57 Therefore, LTB4 might con-
tribute to the pathogenesis of asthma through the re-
cruitment and activation of neutrophils and eosino-
phils
BLT1 CONTRIBUTES TO IL-13 PRODUC-
TION FROM T CELLS AND ALLERGIC AIR-
WAY RESPONSES
T cells are thought to play a key role in orchestrating
the disease process through the production of a vari-
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ety of cytokines in asthma . Several studies have
shown that LTB4 may be important for cytokine se-
cretion from T cells in vitro.58-61 Recent studies have
shown that LTB4 acts as an important attractant for
differentiated T cells. In vivo, we have shown that the
expression of BLT1 can play an important role in IL-
13 production from T cells and the full development
of allergen-induced AHR. 62 Using BLT1 −− mice
with a targeted disruption of the receptor, allergen-
induced AHR was significantly reduced compared to
BLT1++ mice. Numbers of BAL eosinophils were
similar in both strains of mice as were serum levels of
antigen-specific IgE and IgG1. In vivo IL-13 produc-
tion from lung cells was significantly reduced in the
deficient mice following sensitization and challenge.
BLT1 expression on CD4+ and CD8+ T cells may be
critical in mediating effector function of lung T cells,
especially a subset committed to IL-13 production be-
cause the numbers of IL-13+CD4+ and IL-13
CD8+ T cells in the lung were significantly lower than
in BLT1++ mice. Further, in vitro IL-13 production
by lung BLT1−− T cells was lower than in BLT1++
T cells.62 Following transfer of antigen-primed BLT1
++ T, but not naive BLT1++ T cells, the develop-
ment of AHR and levels of IL-13 were fully restored in
the BLT1−− mice. These data suggest that the BLT1
contribution to the development of AHR may be
linked to IL-13 production from recruited T cells. Fol-
lowing sensitization and challenge, the numbers of
IL-13+CD4 and IL-13+CD8 in the spleen were not
different between the 2 strains of mice, suggesting
that BLT1 contributes more to the recruitment of IL-
13 producing T cells to the lung rather than func-
tional activation of these types of T cells. Turner et al.
have also reported that CP-105696, an antagonist of
the LTB4 receptor , suppressed AHR in a primate
model , 63 consistent with our data . Using different
strains of BLT1 mice, Terawaki et al. also reported at-
tenuated AHR in BLT1-deficient mice, which were es-
tablished independently from the ones we used. In
their study, BLT1-deficient mice on a C57BL6 back-
ground exhibited reduced AHR and decreased cy-
tokine IL-13 in BAL.64 The production of IL-4 and IL-5
as well as IL-13 from cultures of peribronchial
lymphnode (PBLN) cells were also attenuated with
BLT1 deficiency , suggesting that the LTB4-BLT1
pathway may be required for functional activation of
Th2-type cells. Thus, the contribution of BLT1 to IL-
13 production from lung T cells may be not only
through recruitment of subsets of these cells capable
of IL-13 production, but also the functional activation
of these cells to produce IL-13
Interestingly, airway responses induced by recom-
binant IL-13 may require an intact LTB4 pathway in
vivo,65 suggesting that the LTB4 pathway may also be
involved in these IL-13-induced and dependent
events. Since effector T cells in the lung are a source
of IL-13 following allergen-challenge, this release of
IL-13 may further activate LTB4 production in the
lung and serve to amplify or enhance the accumula-
tion and activation of IL-13 producing effector T cells
LTB4-DIRECTED ANTIGEN-SPECIFIC EF-
FECTOR CD 8 + T-CELL TRAFFICKING IN
ASTHMA
In contrast to the role of CD4+ T cells in allergic air-
way disease, the contribution of CD8+ T cells to the
development of allergic airway disease is more con-
troversial and has been more difficult to define. This
may be due to the functional heterogeneity of CD8+ T
cell subpopulations involved in different phases of the
development of an allergic airway response . Cur-
rently , there is increasing evidence indicating the
contribution of CD8+ T cells to allergic airway re-
sponses.4-10 We have recently shown that following
sensitization and allergen exposure, mice deficient in
the CD8+ chain developed less airway inflammation
and AHR compared to wild-type mice.7 This was asso-
ciated with decreased levels of the TH2 cytokine IL-
13 in BAL fluid. Transfer of CD8+ T cells from sensi-
tized, but not from naive donors , prior to allergen
challenge fully reconstituted the development of air-
way inflammation, IL-13, and AHR in sensitized CD8-
deficient mice, emphasizing that “allergen priming” is
necessary for the supportive function of CD8+ T cells,
similar to that shown with CD4+ T cells.66 To further
characterize the role of CD8 T cells, we differentiated
antigen-specific TEFF and TCM from OVA257-264 (SIIN-
FEKL) peptide-specific TCR transgenic mice in the
presence of IL-2 (TEFF) and IL-15 (TCM), respectively.
Reconstitution of CD8−− mice with TEFF increased
AHR, lung eosinophilia and IL-13 levels, whereas TCM
failed to do so. The TEFF accumulated in the lung,
whereas the TCM were detected in the PBLN . In-
creased numbers of CD8+IL-13+ cells were found in
the lungs of recipients following transfer of TEFF.
These data further link CD8+ T cells and effector CD
8+ T cells in particular with the full development of
AHR and airway inflammation
As discussed above, the LTB4-BLT1 pathway ap-
pears to play an important role in the recruitmentac-
tivation of IL-13 producing T cells in the lung. As pre-
viously described, in vitro generated CD8 TEFF ex-
press higher mRNA levels of the LTB4 high affinity
receptor, BLT1, than CD8 TCM.34,35 To investigate di-
rectly whether BLT1 expression was essential for the
development of CD8-mediated allergen-induced AHR
and inflammation, we adoptively transferred BLT1++
or BLT1−− CD8 or in vitro generated CD8 TEFF into
the CD8−− mice.67 Only CD8 or TEFF expressing
BLT1 were effective in fully reconstituting all of the
responses, including IL-13, identifying the essential
role of this LTB4 receptor on CD8 T cells. Further,
only BLT1+CD8+IL-13+ T cells were significantly
increased in the lungs or BAL of sensitized and chal-
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Fig. 1 Potential mechanisms of alergic airway disease in sensitized hosts folow-
ing alergen exposure. Folowing alergen exposure, activation of mast cels via the 
high afinity Fc receptor for IgE (FcεRI) leads to mast cel activation, triggering re-
lease of mediators including lipid mediators such as leukotriene B4 (LTB4). LTB4-
BLT1 (leukotriene B4 receptor 1) interaction leads to the recruitment/activation of 
alergen-specific CD4+ type-2 helper T cels (TH2) and alergen-specific efector 
CD8+ T cels (TEFF). In the mast cel-independent pathway, alergen exposure 
leads to recruitment of efector T cels likely through LTB4 generated by other cel 
types (e.g., macrophages). Efector T cels produce IL-13. IL-13 then acts on air-
way epithelial cels to induce goblet cel (GC) metaplasia and on airway smooth 



















lenged recipients and in much higher numbers .
Tager et al. reported that trafficking of TEFF into the
airway did not differ in the presence or absence of
this receptor following adoptive transfer and airway
challenge of naive (non-sensitized) recipients . 33 In
contrast, using sensitized as opposed to naive recipi-
ent mice, we showed that migration of transferred
BLT1−− TEFF into the lung as well as BAL was sig-
nificantly impaired compared to BLT1++ TEFF. In
this adoptive transfer model, the recipient mice were
sensitized to OVA (plus alum) prior to OVA chal-
lenge. LTB4 production in the lungs of sensitized and
challenged recipients should be significantly higher
than challenged only recipients , 68 and these in-
creased levels of LTB4 may play a pivotal role in en-
hancing the recruitment of transferred BLT1++ TEFF
into the lung. In a different lung disease model, BLT1
has also shown to contribute to the development of
lung rejection and obliterative bronchiolitis by medi-
ating effector CD8+ T cell trafficking into the lung.69
Different members of the chemokine family are
known to be subset-selective chemoattractants for T
cells. CCL2 and CCL5 may be important in the re-
cruitment of CD8+ T cells.38 TEFF were reported to mi-
grate in response to CCL5 as well as LTB4 in vitro.35
It appears that LTB4-dependent signals contribute at
least one essential link to a chain of molecular events
that may be required for efficient recruitment of TEFF
to the allergic airways
IGE-FCεRI-MAST CELL-CD8-BLT1-IL-13
CONNECTION
The studies in mice described above were generated
in sensitized and challenged mice. This experimental
model is believed to be IgE and mast cell-
independent because mast-cell deficient mice and B-
cell-deficient mice develop similar degrees of airway
allergic responses as their respective normal litter-
mates . 70,71 Somewhat in parallel , we examined re-
sponses in a mast cell-dependent system. Briefly, us-
ing a 10-day allergen exposure approach , FcεRI-
deficient mice failed to develop altered airway func-
tion, less airway inflammation, and lower IL-13 levels.
Transfer of WT bone marrow-derived mast cells
(BMMC) fully restored these responses in FcεRI−−
mice and transferred mast cells could be detected in
the tracheal preparations when derived from UBI-
GFP mice, suggesting that IgE-FcεRI-mast cells are
involved in the responses to 10 days of airway aller-
gen exposure .72 IL-13 was shown to be critical to
these responses as they were absent in IL-13−− mice
and prevented in WT mice treated with an IL-13 re-
ceptor antagonist. Transfer of WT BMMC into IL-13
−− mice failed to restore the responses, however,
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transfer of IL-13−− BMMC into FcεRI−− mice did
restore the responses, suggesting that IL-13 was in-
deed derived from another cell type other than the
mast cell.72 CD8+ T cells were shown to be required
for development of altered airway responsiveness.6
Using a passive sensitization model to avoid any
potential interference on the host’s ability to make
IgE,73 we examined a number of different mice. Here,
mice were passively sensitized by injection of allergen-
specific IgE prior to airway challenge . Mast cell-
deficient, FcεRI−−, IL-13−−, BLT1−−, and CD8−−
mice all failed to develop alterations in airway respon-
siveness following passive sensitization with OVA-
specific IgE and limited airway allergen challenge
( unpublished observations ) .74 Recipient CD8 −−
mice, reconstituted with CD8+ TEFF, restored all of
the responses. Moreover, only TEFF expressing BLT1
but not BLT1−− TEFF were capable of doing so. The
numbers of BLT1 + TEFF cells were significantly
higher than those of BLT−− TEFF in the lungs of re-
cipients. In addition, the induction of increased air-
way responsiveness and their accumulation in the
lung following transfer of BLT1CD8+ TEFF could
be blocked by administration of an LTB4 receptor an-
tagonist . In parallel , we monitored BAL levels of
LTB4. LTB4 levels in mast cell-deficient and FcεRI-
deficient mice were significantly lower compared to
their respective littermates following passive sensiti-
zation and challenge, suggesting that mast cells were
the primary source of LTB4 following passive sensiti-
zation and allergen challenge . Thus , in both mast
cell-independent and mast cell-dependent systems ,
there is strong support for an LTB4-BLT1-CD8-IL-13
module (Fig. 1).
CONCLUSIONS
Although the importance of LTB4 in allergic airway
disease has been suggested for over two decades, re-
cent experimental evidence now indicates a critical
role for an LTB4-BLT1 pathway in IL-13 production
from T lymphocytes and recruitment of antigen-
specific effector CD8+ T cells in both mast cell de-
pendent and independent allergic airway responses.
The cumulative data indicate that control of this
LTB4-BLT1 pathway should provide novel therapeu-
tic opportunities for the treatment of asthma.
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